Video

Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC

Author(s):

Holger L. Gieschen, MD

In Partnership With:

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non—small cell lung cancer (NSCLC).

Side effects of radiation may include skin reactions and some irritation of the lung. Physicians will usually differentiate between acute side effects that may occur when the patient is undergoing treatment and long-term side effects that may manifest months or years after the treatment.

The acute side effects are usually transient and are not cause for concern. Long-term side effects can result in lung fibrosis and diminished lung volume and capacity. As in surgery, the concern is a patient’s insufficient lung capacity after treatment.

One of the most significant side effects that can result from radiation therapy is radiation pneumonitis, which is not due to bacteria or infection, but the radiation itself. Some of these patients require steroid treatments which can be difficult to handle.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Bradley G. Somer, MD, of West Cancer Center & Research Institute
March 27th 2024

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
December 20th 2021

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

Devika Das, MD, MSHQS
March 20th 2023

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
February 25th 2021

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

Lee S. Schwartzberg, MD, of West Cancer Center
December 22nd 2021

Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL